United States - English - NLM (National Library of Medicine)

starman consulting llc - methyl salicylate (unii: lav5u5022y) (salicylic acid - unii:o414pz4lpz) - methyl salicylate 20 g in 100 g - pain & muscle relief for the temporary relief of minor aches and pains of muscles and joints. do not use otherwise than as directed. do not use on wounds or broken skin. do not use if known sensitivity to neuromax exists, or if allergic to salicylate or any ingredients of this product stop use and ask a doctor if skin irritation occurs or gets worse, symptoms persist for more than 7 days,  or symptoms clear up and occur within a few days.

United States - English - NLM (National Library of Medicine)

amrutanjan health care limited - menthol 15.0%, methyl salicylate  15% - menthol                    topical analgesic methyl salicylate      topical analgesic - temporarily relieves pain associated with headache, cold, body ache and nasal congestion - provides temporary relief of minor pains of muscles and joints - condition worsens - redness or irritation develops - symptoms persist for more than 7 days or clear up and occur again within a few days or is accompanied by fever, rash, or persistent headaches

United States - English - NLM (National Library of Medicine)

amrutanjan health care limited - camphor (synthetic) (unii: 5tjd82a1et) (camphor (synthetic) - unii:5tjd82a1et), menthol (unii: l7t10eip3a) (menthol - unii:l7t10eip3a), methyl salicylate (unii: lav5u5022y) (salicylic acid - unii:o414pz4lpz) - camphor                           topical analgesic menthol                             topical analgesic methyl salicylate               topical analgesic - temporarily relieves pain associated with headache, cold, body ache and nasal congestion - provides temporary relief of minor pains of muscles and joints - avoid contact with eyes - do not use otherwise than as directed - condition worsens - redness or irritation develops - symptoms persist for more than 7 days or clear up and occur again within a few days or is accompanied by fever, rash, or persistent headaches

United States - English - NLM (National Library of Medicine)

luoyang muchun pharmaceutical co, ltd - menthol     8% methyl salicylate     26% - menthol      topical analgesic methyl salicylate      topical analgesic for temporary relief of minor aches and pains of muscles and joints associated with arthritis, simple backache, strains, sprains, and bruises. condition worsens. symptoms persist for more than 7 days or clear up and occur again within a few days. people with allergic conditution consult a doctor before using.

United States - English - NLM (National Library of Medicine)

dominion veterinary laboratories ltd. - camphor  3.35%, povidone iodine  5.10%, methyl salicylate  9.88% - for use of temporary relief of minor stiffness and soreness. not for use in food producing animals. avoid contact with the eyes or mucous membranes. do not apply to wounds or damaged skin. do not apply to irritated skin or if exessive irritation develops. do not bandage tightly. if klameness persists or if excessive irritation develops, discontinue use and consult a veterinarian.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

kotra pharma (m) sdn. bhd. - methyl salicylate; menthol crystal -

New Zealand - English - Medsafe (Medicines Safety Authority)

psm healthcare ltd trading as api consumer brands - cineole 2.5%; menthol 10%;  ;  ; methyl salicylate 50%;   - topical ointment - active: cineole 2.5% menthol 10%     methyl salicylate 50%   excipient: cajuput oil lanolin water white beeswax

United States - English - NLM (National Library of Medicine)

a-s medication solutions - methylprednisolone (unii: x4w7zr7023) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone 4 mg - methylprednisolone tablets are indicated in the following conditions: - endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditis primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditis - rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: rheumatoid arthritis, including juvenile rheumatoid arthritis (selected ca

United States - English - NLM (National Library of Medicine)

lannett company, inc. - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 18 mg - methylphenidate hcl extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children 6 years of age and older, adolescents, and adults up to the age of 65 [see clinical studies (14)] . a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; e

United States - English - NLM (National Library of Medicine)

mayne pharma - methylphenidate hydrochloride (unii: 4b3sc438hi) (methylphenidate - unii:207zz9qz49) - methylphenidate hydrochloride 20 mg - methylphenidate hydrochloride extended-release capsules (la) are indicated for the treatment of attention deficit hyperactivity disorder (adhd). the efficacy of methylphenidate hydrochloride extended-release capsules (la) in the treatment of adhd was established in 1 controlled trial of children aged 6 to 12 who met dsm-iv criteria for adhd (see clinical pharmacology). a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor